Clinical trial BIONIC
Prospective observational study on the clinical efficacy of bispecific antibodies in patients with relapsed and refractory multiple myeloma (BIONIC)
| Organ | Myeloma |
|---|---|
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Prospective observational study
|
| Academic trial | Oui |
| Sponsor | UZ-K.U.Leuven |
| BECT Identifier | B3222024001538 |
| Inclusion criteria | Age 18 years or older- Written informed consent- Has a diagnosis of relapsed and refractory multiple myeloma- Has already received at least 3 previous treatments - Is refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, a |
| Last update |